In addition, TXYF is also found to decrease the levels of gastroenteric hormones, such as 5-HT, substance P (SP), vasoactive intestinal peptide (VIP), somatostatin (SS), and cholecystokinin (CCK) in rats and humans with IBS [47, 48]. Here, TFF2 is linked to irritable bowel syndrome.